Design Controls for Drug-Led Combination Products: What FDA Expects in 2023 Design Controls for Drug-Led Combination Products: What FDA Expects in 2023 In the evolving landscape of healthcare, drug-led combination products present unique regulatory challenges and opportunities. Navigating the Food and Drug Administration (FDA) requirements for these products is crucial for regulatory affairs professionals. This tutorial will provide a clear, step-by-step guide for understanding and implementing design controls as mandated by the FDA for combination products in 2023. Step 1: Understanding Combination Products The first step in complying with the FDA regulations regarding drug-led combination products is to have a…

510(k) Use in Combination Products: Leveraging Predicates Without Creating New PMOA Risk in 2023 510(k) Use in Combination Products: Leveraging Predicates Without Creating New PMOA Risk in 2023 As regulatory professionals navigate the complexities of the FDA’s combination product regulations, understanding the 510(k) process is crucial for ensuring compliance and market readiness. This article provides a detailed step-by-step tutorial on using 510(k) submissions effectively within the context of combination products, guiding you through each essential phase with a focus on practical actions and documentation expectations. Our target audience includes regulatory affairs professionals, quality assurance teams, and commercial stakeholders primarily engaged…

Postmarket Safety Reporting Final Rule: US Compliance Checklist for Combination Products in 2023 Postmarket Safety Reporting Final Rule: US Compliance Checklist for Combination Products in 2023 The Postmarket Safety Reporting Final Rule introduced by the FDA significantly alters the landscape of regulatory compliance for combination products. Combination products, which combine drug, device, and biological components, require a nuanced approach to postmarket safety reporting. Understanding the requirements and systematic implementation of these regulations is essential for stakeholders involved in FDA combination product consulting. This article serves as a comprehensive guide for US-based regulatory affairs professionals, quality assurance teams, and commercial stakeholders,…

Pre-Submission Meeting Package for Combination Products: US Template and Must-Haves in 2023 Pre-Submission Meeting Package for Combination Products: US Template and Must-Haves in 2023 The development and approval of combination products in the United States can be a complex process, necessitating effective communication with regulatory agencies. A Pre-Submission Meeting (PSM) offers an essential opportunity to discuss product development, regulatory expectations, and pathways before formal submissions. This detailed tutorial serves as a guide for regulatory affairs professionals in preparing and conducting a Pre-Submission Meeting Package for combination products, conforming to the guidelines set forth by the FDA’s Office of Combination Products…